Consequently, it can be deduced that ‘activation of TRPV1 can inhibit breast cancer cell proliferation’, and the conclusion that ‘further development and application of TRPV1 agonists can be anti-tumour in terms of inhibiting proliferation’. This evidence concerns the gene TRPV1 and neoplasm.